News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Related Content
Trending on PharmExec
1
The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan
2
Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics
3
FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease
4
Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD
5